The Dexcom logo will appear on your smartphone screen and background.
Pablo Gonchar | SOPA Images | Light Rocket | Getty Images
dexcom The company on Tuesday unveiled artificial intelligence features in its Stelo continuous blood glucose monitor that can give users a personalized view of how their diet, sleep and activity affect their blood sugar levels. This is the first iteration of a new generative AI platform the company has been building. google cloud.
Stelo is a commercially available CGM that measures real-time blood sugar levels through the skin. The sensor was launched in August and can be used by any adult who does not take insulin.
This report reflects Dexcom’s efforts to make Stelo more personalized and appealing to consumers as it moves into new markets.
“The number one feedback we get is that users want to see more,” Jake Leach, Dexcom’s chief operating officer, told CNBC in an interview. “They are investing and wearing the product, and they want to be able to make the most of all the data that is being generated.”
Dexcom is using Google’s Gemini model and Vertex AI platform as the foundation for its new AI services. Vertex AI allows developers to build applications that synthesize different types of data, which can be notorious in the medical field.
Leach said Dexcom is also looking at how its generative AI platform can be used with other CGM products, but patients rely on it to prevent medical emergencies. Therefore, the company said it is proceeding with the work with particular caution.
“We really felt like Stelo was the perfect place to do this for the first time,” he said.
The existing Insights report was already available to users within the Stelo app, but it followed a more standard template format each week. Dexcom believes that AI-generated reports will be more valuable to users because they are personalized, Leach said.
For example, if a user has a week where they don’t move enough after meals, the report will include helpful tips and educational materials.
While Stelo’s AI report does not provide medical advice to users, Leach said Dexcom is using the U.S. Food and Drug Administration’s AI framework to guide the development of the feature. . The FDA approved Stelo in March.
Ultimately, Dexcom wants to use its generative AI platform to provide users with real-time feedback rather than just weekly reports. The company is also exploring the possibility that the technology could serve as a predictive indicator of potential problems, much like a car’s check engine light.
“You’ll be able to understand what’s going on and get recommendations on where to go for further advice,” Chris Sakalosky, Google Cloud’s vice president of strategic industries, said in an interview with CNBC. spoke.
Dexcom’s updated weekly reports began rolling out to Stelo users this week.
